Get notified when MMED files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Sole Supplier Fda Warning Letter (new) — Unomedical, sole supplier of infusion sets, received FDA warning letter Jan 2026 for QSR violations including process-validation failures linked to patient injuries; could trigger supply disruption or recalls.
- Manufacturing Scale-Up Failure (new) — Simplera CGM automated manufacturing lines failed to meet throughput/yield requirements; company terminated third-party arrangement and recorded $118M charge, with uncertain timeline for successful high-volume production.
- Controlled-Company Structure (new) — Medtronic controls 90% of voting power, enabling unilateral control over all stockholder matters including business direction, mergers, and financing; company relies on Nasdaq controlled-company governance exemptions.
MiniMed (MMED) posts first 10-K as public company: $3.1B revenue, $317M net loss
Filed June 29, 2026 · Period ending April 24, 2026 · ~2 min read
Key Changes
-
high
Net loss widened to $317M in FY2026 from $198M in FY2025 despite 14% revenue growth to $3.1B, driven by $157M Blackstone royalty charge tied to MiniMed Flex launch and $84M manufacturing asset write-offs from terminated third-party agreement.
MD&A: Financial Results verify on EDGAR → -
high
Sole infusion-set supplier Unomedical received FDA warning letter Jan 2026 citing process-validation failures for leak detection linked to patient injuries (hyperglycemia, DKA), inadequate complaint investigation, and late medical-device reporting; supply disruption could materially impact operations.
Risk Factors: Supply Chain verify on EDGAR → -
high
Simplera CGM production scaling slower than planned after failed high-volume automated manufacturing lines; company terminated third-party manufacturer arrangement and recorded $118M pre-tax charge in FY2026.
Risk Factors: Manufacturing verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MSM 10-Q) is open in full — no account needed.
Partner
Trade MMED commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 6, 2026 · How we verify